Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 8,700 Shares of Teleflex Incorporated $TFX

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in Teleflex Incorporated (NYSE:TFX) by 74.7% in the 1st quarter, Holdings Channel reports. The firm owned 2,944 shares of the medical technology company’s stock after selling 8,700 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Teleflex were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of TFX. Barclays PLC lifted its position in Teleflex by 20.9% in the fourth quarter. Barclays PLC now owns 108,689 shares of the medical technology company’s stock worth $19,344,000 after purchasing an additional 18,782 shares during the period. Mariner LLC lifted its position in Teleflex by 7.9% in the fourth quarter. Mariner LLC now owns 5,430 shares of the medical technology company’s stock worth $966,000 after purchasing an additional 396 shares during the period. Walleye Capital LLC lifted its position in Teleflex by 420.2% in the fourth quarter. Walleye Capital LLC now owns 6,695 shares of the medical technology company’s stock worth $1,192,000 after purchasing an additional 5,408 shares during the period. Jump Financial LLC bought a new position in Teleflex in the fourth quarter worth $1,595,000. Finally, Marshall Wace LLP raised its stake in Teleflex by 8.4% during the fourth quarter. Marshall Wace LLP now owns 55,087 shares of the medical technology company’s stock worth $9,804,000 after acquiring an additional 4,284 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on TFX. Wall Street Zen upgraded Teleflex from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Morgan Stanley dropped their price objective on Teleflex from $191.00 to $173.00 and set an “overweight” rating for the company in a research note on Monday, May 5th. Truist Financial dropped their price objective on Teleflex from $140.00 to $137.00 and set a “hold” rating for the company in a research note on Monday, May 5th. Wells Fargo & Company dropped their price objective on Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Finally, Royal Bank Of Canada increased their price objective on Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a research note on Friday, August 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $141.57.

Insiders Place Their Bets

In other news, Director Gretchen R. Haggerty purchased 500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average price of $114.75 per share, for a total transaction of $57,375.00. Following the completion of the acquisition, the director directly owned 6,305 shares in the company, valued at approximately $723,498.75. The trade was a 8.61% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew A. Krakauer purchased 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average price of $115.25 per share, for a total transaction of $115,250.00. Following the acquisition, the director owned 7,192 shares of the company’s stock, valued at $828,878. The trade was a 16.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 5,500 shares of company stock valued at $633,590 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Teleflex Price Performance

Shares of TFX stock opened at $121.00 on Monday. The stock’s fifty day moving average is $117.93 and its 200-day moving average is $132.12. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The stock has a market capitalization of $5.35 billion, a PE ratio of 28.47, a PEG ratio of 1.68 and a beta of 1.08. Teleflex Incorporated has a 52 week low of $108.90 and a 52 week high of $249.90.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.36 by $0.37. The company had revenue of $780.90 million for the quarter, compared to analysts’ expectations of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.42 earnings per share. Equities research analysts expect that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be issued a $0.34 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.36 annualized dividend and a yield of 1.1%. Teleflex’s dividend payout ratio (DPR) is currently 32.00%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.